VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-1.04%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$165M
AUM Growth
-$4.08M
(-2.4%)
Cap. Flow
+$1.01M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54
Top Buys
| 1 |
Halliburton
HAL
|
$819K |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$814K |
| 3 |
Steel Dynamics
STLD
|
$798K |
| 4 |
Caterpillar
CAT
|
$792K |
| 5 |
Booking.com
BKNG
|
$789K |
Top Sells
| 1 |
Netflix
NFLX
|
$1.05M |
| 2 |
Vulcan Materials
VMC
|
$1.01M |
| 3 |
CoStar Group
CSGP
|
$998K |
| 4 |
Eli Lilly
LLY
|
$967K |
| 5 |
Ingersoll Rand
IR
|
$913K |
Sector Composition
| 1 | Healthcare | 18.63% |
| 2 | Financials | 17.26% |
| 3 | Technology | 14.89% |
| 4 | Energy | 9.42% |
| 5 | Consumer Discretionary | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Merus
MRUS
$5.1B
| $88K | 0.05% |
3,731
-372
| -9% | -$8.77K |
|
352
Cytokinetics
CYTK
$6.34B
| $83.2K | 0.05% |
2,824
-282
| -9% | -$8.31K |
|
353
Alector
ALEC
$305M
| $83.1K | 0.05% |
12,831
-1,273
| -9% | -$8.25K |
|
|
SWTX
354
DELISTED
SpringWorks Therapeutics
SWTX
| $83K | 0.05% |
3,590
-356
| -9% | -$8.23K |
|
|
IGMS
355
DELISTED
IGM Biosciences
IGMS
| $82.7K | 0.05% |
9,909
-987
| -9% | -$8.24K |
|
356
Regenxbio
RGNX
$490M
| $82.7K | 0.05% |
5,025
-498
| -9% | -$8.2K |
|
357
Keros Therapeutics
KROS
$633M
| $81.6K | 0.05% |
2,561
-257
| -9% | -$8.19K |
|
358
Arbutus Biopharma
ABUS
$805M
| $81.3K | 0.05% |
40,040
-3,984
| -9% | -$8.09K |
|
359
Zentalis Pharmaceuticals
ZNTL
$126M
| $80.5K | 0.05% |
4,012
-403
| -9% | -$8.08K |
|
360
Phathom Pharmaceuticals
PHAT
$875M
| $80.3K | 0.05% |
7,744
-771
| -9% | -$8K |
|
361
Liquidia Corp
LQDA
$2.48B
| $79.7K | 0.05% |
12,566
-1,251
| -9% | -$7.93K |
|
362
Xenon Pharmaceuticals
XENE
$3.02B
| $79.4K | 0.05% |
2,324
-228
| -9% | -$7.79K |
|
363
Kura Oncology
KURA
$713M
| $78.7K | 0.05% |
8,624
-856
| -9% | -$7.81K |
|
|
AMAM
364
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $78.1K | 0.05% |
6,793
-675
| -9% | -$7.76K |
|
365
RAPT Therapeutics
RAPT
$214M
| $78K | 0.05% |
586
-58
| -9% | -$7.72K |
|
|
ITOS
366
DELISTED
iTeos Therapeutics
ITOS
| $77.4K | 0.05% |
7,066
-707
| -9% | -$7.74K |
|
367
Recursion Pharmaceuticals
RXRX
$2.01B
| $76.7K | 0.05% |
10,032
-996
| -9% | -$7.62K |
|
|
VERV
368
DELISTED
Verve Therapeutics
VERV
| $76.7K | 0.05% |
5,782
-577
| -9% | -$7.65K |
|
369
CRISPR Therapeutics
CRSP
$4.99B
| $76.3K | 0.05% |
1,681
-163
| -9% | -$7.4K |
|
370
Cullinan Oncology
CGEM
$413M
| $76.1K | 0.05% |
8,404
-835
| -9% | -$7.56K |
|
371
Zymeworks
ZYME
$1.14B
| $75.3K | 0.05% |
11,871
-1,183
| -9% | -$7.5K |
|
372
Arrowhead Research
ARWR
$4.02B
| $75.2K | 0.05% |
2,799
-278
| -9% | -$7.47K |
|
373
Cogent Biosciences
COGT
$1.82B
| $75.1K | 0.05% |
7,700
-762
| -9% | -$7.43K |
|
374
Xencor
XNCR
$610M
| $75K | 0.05% |
3,722
-375
| -9% | -$7.56K |
|
|
BCYC
375
Bicycle Therapeutics
BCYC
$483M
| $74.4K | 0.05% |
3,705
-369
| -9% | -$7.41K |
|